VIEWS

AUGUST 2019 CANCER DISCOVERY | 1001

IN THE SPOTLIGHT

A Single-Cell Window into Pancreas Cancer Fibroblast Heterogeneity Jad I. Belle 1 and David G. DeNardo 1 , 2

1 Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. 2 Department of Pathology and Immunology, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri. Corresponding Author: David G. DeNardo, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8069, St. Louis, MO 63110. Phone: 314-362-9524; Fax: 314-747-2797; E-mail: ddenardo@wustl.edu Cancer Discov 2019;9:1001–2 doi: 10.1158/2159-8290.CD-19-0576 ©2019 American Association for Cancer Research.

Summary: Cancer-associated fi broblasts (CAF) have been implicated in diverse and sometimes divergent tumor modulatory processes that can be explained only by the existence of heterogeneous CAF subsets. In this issue of Cancer Discovery , Elyada and colleagues utilize single-cell transcriptomics to resolve CAF heterogeneity in pancreatic ductal adenocarcinoma and identify a novel antigen-presenting CAF population.

See related article by Elyada et al., p. 1102 (5).

The clinical impact that tumor-associated fi brosis can have on tumor aggressiveness and resistance to therapy has become increasingly clear in recent years. In addition, the role of cancer-associated fi broblasts (CAF) as master regulators of fi brotic responses within the tumor microenvironment (TME) is well established. CAFs have been implicated in vari-ous tumor-supportive processes, including tumor growth and metastasis, angiogenesis, immune suppression, and fi bro-sis ( 1 ). Classically, we have also appreciated that activated fi broblasts are essential to isolating pathologically injured or infected tissues to protect the host. Nonetheless, in the context of cancer, the exact functions of CAFs continue to be debated, and this debate is most highly relevant in pancreatic ductal adenocarcinoma (PDAC), a disease characterized by dramatic tumor-associated desmoplasia. In some PDAC mod-els, depletion of specifi c CAF subsets slows PDAC progression and improves antitumor immunity ( 2 ), whereas in other models, depletion of CAFs accelerates PDAC progression ( 3 ). These seemingly confl icting fi ndings may be reconciled by the previously unappreciated heterogeneity of mesenchymal subsets present in PDAC tumors ( 4 ). In this issue of Cancer Discovery , work by Elyada and colleagues using compara-tive single-cell transcriptomics on human and mouse PDAC brings CAF heterogeneity to the fore ( 5 ).

Previous work from this group identifi ed two major CAF populations in mouse models of PDAC. One is an infl am-matory (iCAF) subset characterized by Ly6C expression, JAK/STAT signaling, and a secretory phenotype; and the second is a myofi broblastic (myCAF) subset characterized by SMA expression, TGFβ signaling, and extracellular matrix (ECM) production ( 6 ). These subsets also have unique spatial organi-

zation, whereby myCAFs proximally surround tumor ducts and interact with tumor cells through juxtacrine mecha-nisms, whereas iCAFs reside at greater distances within the stroma and interact with tumor cells, myCAFs, and likely other stromal cells, through infl ammatory cytokines. This study by Elyada and colleagues demonstrates that both CAF populations can be observed in human PDAC and in the KPC genetic model of PDAC. Furthermore, these CAF subsets have been independently corroborated by a more limited single-cell analysis of human PDAC and precursor neoplastic lesions, reported by Bernard and colleagues ( 7 ). The exact role of these subsets in human disease, their heterogeneity across patients and disease stages, and the impact of therapeutically targeting them remain to be explored.

The Elyada study also goes beyond previous fi ndings to identify a novel CAF subset that the authors named antigen-presenting (apCAF) based on expression of MHC class II and Cd74. The presence of this subset was confi rmed by fl ow cytometric and IHC evaluation of mouse and human PDAC. apCAFs were characterized by activation of STAT1, MTORC1, MYC, and antigen presentation pathways. On a functional level, ex vivo studies demonstrated a capacity for apCAFs to activate CD4 + T cells, albeit at much lower levels than profes-sional immune compartment antigen-presenting cells (APC). Moreover, because apCAFs do not express MHCII costimula-tory molecules at levels similar to professional APCs, they could not stimulate proliferation of CD4 + T cells ex vivo . Nev-ertheless, the existence of a functional MHCII + CAF subset is intriguing, especially considering the characteristically immu-nosuppressive and immunotherapy-resistant TME in PDAC.

Fibroblasts are classically known for their roles as media-tors of fi brosis and ECM remodeling; however, the identifi ca-tion of putative immunomodulatory CAF subsets in PDAC and other tumor types implies a novel role for CAFs in regu-lating antitumor immunity. Although this is the fi rst report of MHCII expression on CAFs, MHCII-expressing fi broblasts have been implicated in regulating the development and priming of T cells in the thymus and lymph nodes, and in fi brotic and infl ammatory disease–associated fi broblasts in tissues such as the skin and joints. Therefore, it is plausible that apCAFs might serve a unique antigen-presenting role in regulating T-cell priming and activity within the PDAC TME, potentially by acting as decoy APCs or through interactions

Research. on August 8, 2021. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from

VIEWS

1002 | CANCER DISCOVERY AUGUST 2019 www.aacrjournals.org

with professional APCs such as macrophages. apCAFs might also represent an intermediate phenotype between CAFs and macrophages as the populations have shared properties, including expression of ECM remodeling regulators and antigen-presentation mediators.

The extent to which fibroblast heterogeneity is repli-cated across tissues and disease states remains unknown. To that end, fibroblast heterogeneity has been investigated in other tumor types and in fibrotic diseases. Single-cell transcriptomic analyses of colon cancer patient samples dem-onstrated the existence of unique CAF subsets, with one demonstrating myofibroblastic gene-expression signatures, similar to myCAFs in PDAC (8). Another study identified a CD10+GPR77+ CAF subset in human breast cancer and lung adenocarcinoma that drives cancer-initiating pheno-types, chemoresistance, and tumor growth (9). Also in breast cancer, two studies identified four CAF subsets in patient samples and mouse models. The human study utilized flow cytometric resolution of CAF heterogeneity and functional analyses, which demonstrated immunosuppressive proper-ties of several CAF subsets (10). The mouse study demon-strated origin-related diversity in CAF subsets and suggested potential immunomodulatory roles, although the extent of cross-species concordance was not clear (11). One major potential contributor to CAF diversity that remains to be fully explored is their multiple distinct origins. For example, in pancreatic cancer, CAFs can derive from tissue-resident stellate cells, epithelial cells, adipose tissue, and the bone mar-row. Therefore, it will be important to evaluate the specific origins of CAFs in PDAC and carcinomas of other tissues, and determine whether these origins confer unique pheno-types and functions.

The existence of CAF phenotypic heterogeneity in PDAC has now been established (Fig. 1), yet several outstanding questions remain. It will be essential to evaluate how cancer therapies shift these subsets and the relative influences of each subset on therapeutic resistance and/or response. Spe-cifically, for the apCAFs identified in the Elyada study, the impact of this subset on tumor immunity will be important to understand whether apCAFs are functionally or quanti-tatively modulated in response to immunotherapies. CAF subset profiling of patient samples, such as the data provided here, will be critical in defining the extent of interpatient and intratumoral heterogeneity. As our view of fibroblast hetero-geneity begins to take shape, questions like these will become critical to understanding the impact of CAF diversity on the pathobiology of tumors.

Disclosure of Potential Conflicts of InterestNo potential conflicts of interest were disclosed.

Published first August 1, 2019.

REFERENCES 1. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev

Cancer 2016;16:582–98. 2. Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS,

et al. Targeting CXCL12 from FAP-expressing carcinoma- associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013;110:20212–7.

3. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014;25:719–34.

4. Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 2017;214:579–96.

5. Elyada E, Bolisetty M, Laise P, Flynn WF, Gourtois ET, Burkhart RA, et  al. Cross-species single-cell analysis of pancreatic ductal adeno-carcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov 2019;9:1102–23.

6. Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heteroge-neity in pancreatic ductal adenocarcinoma. Cancer Discov 2019;9: 282–301.

7. Bernard V, Semaan A, Huang J, San Lucas FA, Mulu FC, Stephens BM, et al. Single-cell transcriptomics of pancreatic cancer precursors dem-onstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression. Clin Cancer Res 2019;25:2194–205.

8. Li H, Courtois ET, Sengupta D, Tan Y, Chen KH, Goh JJL, et al. Refer-ence component analysis of single-cell transcriptomes elucidates cel-lular heterogeneity in human colorectal tumors. Nat Genet 2017;49: 708–18.

9. Su S, Chen J, Yao H, Liu J, Yu S, Lao L, et al. CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresist-ance by sustaining cancer stemness. Cell 2018;172:841–56.

10. Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et  al. Fibroblast heterogeneity and immunosuppressive environ-ment in human breast cancer. Cancer Cell 2018;33:463–79.

11. Bartoschek M, Oskolkov N, Bocci M, Lovrot J, Larsson C, Somma-rin M, et  al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun 2018;9:5150.

Figure 1.  Schematic representation of the identified CAF subsets present in PDAC. These include myofibroblastic subsets (myCAF), which proximally surround malignant PDAC cells, and inflammatory CAFs (iCAF) and antigen-presenting CAFs (apCAF), which reside more distally and may regulate immune response (4–6).

PDAC

(myCAF) (iCAF) (apCAF)

αSMA+

Cytokine+

Chemokine+CD4+ T cell

MHCII+ CD74+

myCAF

iCAFImmunecells

apCAF

Research. on August 8, 2021. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from

2019;9:1001-1002. Cancer Discov   Jad I. Belle and David G. DeNardo  HeterogeneityA Single-Cell Window into Pancreas Cancer Fibroblast

  Updated version

  http://cancerdiscovery.aacrjournals.org/content/9/8/1001

Access the most recent version of this article at:

   

   

  Cited articles

  http://cancerdiscovery.aacrjournals.org/content/9/8/1001.full#ref-list-1

This article cites 11 articles, 5 of which you can access for free at:

   

  E-mail alerts related to this article or journal.Sign up to receive free email-alerts

  SubscriptionsReprints and

  .pubs@aacr.orgDepartment at

To order reprints of this article or to subscribe to the journal, contact the AACR Publications

  Permissions

  Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)

.http://cancerdiscovery.aacrjournals.org/content/9/8/1001To request permission to re-use all or part of this article, use this link

Research. on August 8, 2021. © 2019 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from